TLCR is endorsed by the Spanish Lung Cancer Group (SLCG): new horizons for strong academic collaboration in lung cancer
From November 1, 2013, Translational Lung Cancer Research (TLCR) is officially endorsed by the Spanish Lung Cancer Group (figure 1). This is a meaningful milestone for TLCR as an acknowledgment of its expansion and dedication to lung cancer research and will tremendously advance its continued exploration in the field.
The 15th World Conference on Lung Cancer (WCLC 2013) will take place at the Sydney Convention & Exhibition Centre, Sydney, Australia from October 27 through 30, 2013.
In August 2013, Translational Lung Cancer Research is going to launch a special issue on management of Early Stage Non-Small Cell Lung Cancer. This special issue is guest-edited by Dr.Heather Wakelee, from Stanford Cancer Institute, Stanford University, USA. The scope of the special issue will be to provide cutting-edge literature on related fields and a platform for key experts to present their latest research results.
Lung cancer remains the leading cause of cancer related mortality worldwide. With the aim of providing the most up-to-date knowledge in this field, Translational Lung Cancer Research will launch two consecutive special issues in the second quarter of 2013, dedicated to improving the management of patients with lung cancer.
Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), there are about 13 million new cases per year, and 8 million deaths annually, which account for 13% of all human deaths. This mortality figure is projected to rise to 12 million by 2030.
Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) publishes articles that describe new findings in the field of translational research in lung cancer, provides current and practical information on diagnosis, prevention and clinical investigations of lung cancer.